For information about any of these trials, you may contact the individuals who are listed with each trial or study below, or you may contact us at our general USC MS Comprehensive Care Center number (323-442-6870) or email address (mscare@usc.edu).
Please note that appointments to see our doctors for non-research related care may be made by calling the Weiner Neurology Clinic at 323-442-5710.
Cladribine Add-on Study
Status:
Ongoing. Close for Enrollment
Sponsors:
Serono
Type of Study and Brief Description:
A phase II, multi-center, randomized, double-blind, placebo-controlled safety tolerability and efficacy study of add-on cladribine tablet therapy with interferon therapy in relapsing remitting multiple sclerosis subjects with active disease.
Background:
This is a 2 year research study to evaluate the safety, tolerability and efficacy of low-dose oral Cladribine tablets added onto interferon-beta (Ribif, Avenox, Betaseron) subjects with MS experiencing active disease.
Also, researchers wish to see the evolution in brain lesions activity that can occur in MS patients (as measured by MRI), and their possible relationship to any change in MS-related symptoms, relapses, or any change in level of disability.
USC Principal Investigator:
Norm Kachuck, M.D.
Contact:
Jose Aparicio (323-442-6833 or joseapar@usc.edu)
Additional Information:
You can click here for a document that describes more about this trial.
Back to top
|
